Background Multiple myeloma (MM) is an incurable hematologic malignancy, and outcomes remain poor for patients with triple‐class relapsed/refractory MM (RRMM). Descriptive analyses were performed on available data for patient characteristics, disease course, and outcomes of the KCd on triple‐class RRMM patients at our institution. Patients and Methods Twenty‐three patients with triple‐class RRMM treated with KCd between June 2017 and October 2020 were included in our analysis. The regimen KCd consisted of 28 days cycles of carfilzomib 20/36 mg/m2 IV on days 1, 2, 8, 9, 15, and 16, cyclophosphamide 300 mg/m2 IV weekly, and dexamethasone (20‐40) mg orally weekly. Results Patients received a median of 6 (3‐10) prior regimens. The median number of cycles administered was 4 (1‐11) cycles. Overall response rate was 52%, 6 patients (26%) achieved very good partial response (VGPR), 6 patients (26%) achieved partial response (PR), and 5 patients (22%) achieved stable disease (SD). Progression‐free survival (PFS) and Overall‐survival (OS) were 4 and 11.9 months, respectively. There was no reported treatment‐related mortality. The most common grade ≥3 adverse events were neutropenia (26%), thrombocytopenia (56.5%), and anemia (56.5%). Conclusions KCd showed clinically meaningful efficacy and manageable safety profile in patients with triple‐class RRMM in real‐world.